Market open · Delayed intraday data · 2:23 PM ET
Last update: Nov 20, 2026, 2:02 PM ET
Amgen Inc.
$437.49▲ 0.27% today
Market Open

Why Amgen Inc. (AMGN) stock moved

No significant move on Nov 19, 2026 (−1.1%, close-to-close). Latest notable session: Nov 18, 2026.

Latest session▼ 3.1% · Nov 18, 2026 close

Why Amgen Inc. (AMGN) fell 3.1% on November 18, 2026

Amgen Inc. (AMGN) fell 3.1% on November 18, 2026, closing at $443.89 versus $457.93 the prior session (close-to-close, from daily closes). Amgen reaches proposed settlement in securities litigation filed in Southern District of New York. Source: Business Wire.

Updated
Prior close
$457.93
Nov 18, 2026 close
$443.89
Change (close-to-close)
−$14.04
−3.07%
As first detected · Nov 18, 2026, 10:23 AM ET

Amgen reaches proposed settlement in securities litigation filed in Southern District of New York.

What to watch next: Settlement resolves shareholder lawsuit, reducing legal uncertainty and potential financial liability for Amgen.

Source: Business Wire · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved AMGN

  1. −3.8%After reporting Q3 FY2026 earnings on 2026-11-03 that beat consensus EPS by 11.40% ($6.45 reported vs. $5.79 estimate).
  2. +3.7%Amgen reported Q3 earnings and sales that beat consensus, and raised full-year guidance, according to Zacks.
  3. −0.9%Amgen Inc. (AMGN) reported EPS of $6.45 vs. consensus estimate of $5.79, beating by 11.4% on 2026-11-03.
  4. +3.3%Amgen's co-developed asthma drug Tezspire achieved 69% histologic remission in an eosinophilic esophagitis trial, with statistically significant symptom improvement sustained through week 52 versus placebo, per a press release dated 2026-10-20.
  5. +3.2%Driven by institutional buying activity, recent analyst price-target upgrades (UBS raised its target to $470), and optimism around its obesity pipeline candidate MariTide and growth drugs Repatha and Tezspire, according to the web catalyst.
  6. −3.4%We checked news, earnings, analyst updates, and filings — no company-specific catalyst was found.
  7. −10.1%After rival Novartis announced its Phase III cardiovascular trial for pelacarsen failed to meet primary endpoints, raising concerns about similar pipeline risks at AMGN.

Amgen Inc. (AMGN) shares rose 0.3% to $437.49 as of November 20, 2026, a slight gain from the prior close of $436.30. BestStocks flagged the session as a major change for AMGN. The move is tied to company news. Below, we break down what changed for AMGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Company News

Amgen reaches proposed settlement in securities litigation filed in Southern District of New York. Settlement resolves shareholder lawsuit, reducing legal uncertainty and potential financial liability for Amgen.

This summary describes the catalyst and move as first detected on Nov 18, 2026, 10:23 AM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsSector-Wide MoveWeak confidence
Rel. volume
0.6×
Below Avg
Vs peers
Top 5 of 7 peers
In Line With Peers
Market cap
$236.6B
NASDAQ Global Select
Analyst target
$426
-2.6% vs price
Price chart
Nov 20
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Amgen Inc. investors

For Amgen Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.3% session move; Amgen reported Q3 earnings and sales that beat consensus, and raised full-year guidance, according to Zacks. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in AMGN's fundamentals. Wall Street's consensus price target sits at $426.29, implying -2.6% downside from $437.49. Over the past 90 days analysts logged 0 upgrades and 3 downgrades. BestStocks rates the overall signal quality weak (37/100). With earnings roughly 74 days out, the next report is the most likely near-term test of the move.

AMGN price reaction

AMGN last traded at $437.49, up $1.19 (+0.27%) from the previous close of $436.30. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median +1.8% over the same stretch, leaving AMGN behind the group by 1.5 points.

Bullish and bearish analyst opinions on Amgen Inc. (AMGN)

The consensus analyst price target on Amgen Inc. (AMGN) is $426.29, 2.6% below the recent $437.49. Over the past 90 days analysts logged 0 upgrades, 29 maintains, and 3 downgrades. Here is how the bullish and bearish cases on AMGN line up.

The bullish case

  • The Street's most bullish target is $531.00 (+21.4%).
  • Positive 0.3% session move.
  • Amgen reported Q3 earnings and sales that beat consensus, and raised full-year guidance, according to Zacks.
  • Positive price momentum.

The bearish case

  • The consensus analyst price target of $426.29 sits 2.6% below the recent $437.49, so the average target sees limited room to run.
  • The most bearish analyst target is $230.00 (-47.4%).
  • 3 analyst downgrades in the past 90 days, most recently Freedom Broker to Hold (2026-11-06).
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $426-2.6%
= 29 maintains↓ 3 downgrades
Argus Research maintained Buy · 2026-11-12
SEC filings watch
10-Q2026-11-04
Quarterly financial results
medium
8-K2026-11-03
Material event — review for impact
high
8-K2026-10-27
Material event — review for impact
high
10-Q2026-08-05
Quarterly financial results
medium
Peer context
AMGN+0.3%
LLY+0.0%
UNH+3.9%
JNJ+1.8%
PFE+0.2%
ABBV+1.9%

Previous notable changes for AMGN

News2026-11-09
Amgen's Repatha demonstrated cost-effectiveness and 29% cardiovascular event risk reduction in new AHA 2026 trial data.
News2026-11-05
Amgen's Repatha demonstrated 20% heart attack risk reduction versus ezetimibe in largest real-world comparative study of 500,000+ patients.
Filings2026-11-04
Amgen Inc. (AMGN) filed a new 10-Q on November 4, 2026.
Activity2026-11-04via zacks.com ↗
Amgen reported Q3 earnings and sales that beat consensus, and raised full-year guidance, according to Zacks. The stock advanced 2.71% to $473.78 on elevated volume (2.33x average for this time of day). An 8-K material event filing was also submitted today, signaling a substantive corporate action beyond the earnings announcement.
Upcoming catalysts & outlook
Next earnings
2027-02-02 (est.)
in 74 days
10-Q Filing (est.)
2027-02-03
Medium impact
Thesis shift
Neutral / Mixed
bullish signal
Risk level
Low
from change events

Frequently asked questions about AMGN

Why did Amgen Inc. (AMGN) stock move?

Amgen Inc. (AMGN) fell 3.1% on November 18, 2026, closing at $443.89 versus $457.93 the prior session (close-to-close, from daily closes). Amgen reaches proposed settlement in securities litigation filed in Southern District of New York. Source: Business Wire.

How much did AMGN stock rise?

AMGN gained 0.27% ($1.19) versus the prior close of $436.30, last trading at $437.49 on 0.6× average volume.

When is Amgen Inc.'s next earnings date?

AMGN's next earnings report is estimated for 2027-02-02 — about 74 days away.

What is the analyst price target for AMGN?

The consensus analyst price target for AMGN is $426.29, about 2.6% below the current $437.49. Over the past 90 days, analysts recorded 0 upgrades, 29 maintains, and 3 downgrades.

Is the AMGN move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median +1.8% against AMGN's +0.3%. AMGN ranks top 5 of 7 peers.

How BestStocks tracks AMGN

This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for AMGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataCompany news feedsSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.